학술논문
Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
Document Type
Case Study
Author
Source
Subject
*DECITABINE
*DARATUMUMAB
*MULTIPLE myeloma
*ACUTE myeloid leukemia
*VENETOCLAX
*BONE marrow cells
*
*
*
*
*
Language
ISSN
0939-5555
Abstract
The patient died 2 months later of t-AML/MM progression, 50 months after the diagnosis of HR MM, and 9 months after t-AML. Recently, Berthon et al. reported about a patient with simultaneous AML and MM who concomitantly received 5-azacytidine and daratumumab during MM relapse (Suppl. AML treatment with decitabine/venetoclax resulted in complete remission (CR) of the t-AML, while progressive disease of MM was treated with daratumumab. Dear Editor, With increased survival of patients with multiple myeloma (MM), therapy-related myelodysplastic syndrome (t-MDS) and t-acute myeloid leukemia (AML) may occur more frequently [[1]]. [Extracted from the article]